$IMDX News

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

​Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Insight Molecular Diagnostics Inc. 2026 Q1 - Results - Earnings Call Presentation

How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission

Insight Molecular Q1 2026 Earnings Call Transcript

Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...

Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate

iMDx to Release First Quarter 2026 Results on May 13, 2026

How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones

Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay

Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst

How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst

Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary

Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission